Polycystic ovary syndrome affects an estimated 10% to 13% of women of reproductive age worldwide, making it one of the most common hormonal disorders in this population. Despite how prevalent it is, up to 70% of women with PCOS remain undiagnosed.
Global Prevalence by the Numbers
The World Health Organization puts the global estimate at 10% to 13% of women. A large systematic review and meta-analysis published in Human Reproduction Update narrowed this further, finding a global prevalence of about 12% when using the most widely accepted diagnostic standard (the Rotterdam criteria). That means roughly 1 in 8 women of reproductive age has the condition, whether or not they know it.
Prevalence varies by world region. The highest rates appear in the Eastern Mediterranean region (about 15%) and Southeast Asia (about 14%). Europe falls around 12%, the Americas around 10.5%, and the Western Pacific region around 9%. Data from Africa remains scarce, which means the true global picture is still incomplete.
Why Estimates Vary So Much
One reason you’ll see different numbers is that doctors don’t all use the same checklist to diagnose PCOS. Three sets of diagnostic criteria exist, and each one casts a wider or narrower net. The Rotterdam criteria, which require two out of three key features (irregular periods, elevated androgens, or characteristic ovarian appearance on ultrasound), capture the most cases. The older NIH criteria, which require both irregular periods and elevated androgens, identify fewer women. A third standard falls somewhere in between.
In population studies, this difference is significant: global prevalence comes in at about 12% under Rotterdam criteria but closer to 8% under NIH criteria. In clinical settings where women already suspect they have the condition, the gap widens even more. One study of over 100 women self-reporting PCOS symptoms found that 70% met the Rotterdam threshold, while only 53% met the stricter NIH definition. Same group of women, different answers depending on which criteria the doctor uses.
Prevalence in Adolescents
PCOS can begin in adolescence, but pinning down how many teens are affected is harder than it is for adults. Estimates range widely, from about 1% to 11% of adolescent girls globally. Part of the difficulty is that irregular periods and mild acne are normal during puberty, making it easy to either miss the condition or overdiagnose it. Current international guidelines recommend against using pelvic ultrasound to diagnose PCOS in girls who are less than eight years past their first period, specifically because it leads to overdiagnosis.
Teens with type 2 diabetes face higher odds. A meta-analysis in JAMA Network Open found that roughly 1 in 5 girls with type 2 diabetes also had PCOS, a rate far above the general adolescent population.
How Symptoms Differ Across Ethnic Groups
PCOS occurs in all ethnicities, but the way it shows up in the body can differ. A study comparing women with PCOS across racial groups found that Hispanic women had the highest rates of insulin resistance (52% with abnormal levels), elevated androgens (76%), and excess hair growth (94%). Non-Hispanic Black women had lower rates of high triglycerides (just 5%, compared to 28% in white women and 31% in Hispanic women) but higher rates of insulin resistance than white women. Non-Hispanic white women fell in between on most measures.
These differences matter because they affect which complications a woman is most likely to face. A woman with PCOS whose primary issue is insulin resistance has a different risk profile than one whose main symptom is excess androgens, and ethnicity appears to influence which pattern dominates.
The Underdiagnosis Problem
Perhaps the most striking statistic about PCOS isn’t how common it is, but how often it goes unrecognized. The WHO estimates that up to 70% of affected women worldwide have never been diagnosed. That means for every woman who knows she has PCOS, roughly two others are experiencing symptoms without an explanation.
Several factors contribute. Symptoms like irregular periods, weight gain, and acne are often attributed to stress, diet, or normal hormonal fluctuations. Many women don’t receive a diagnosis until they struggle to conceive, which can be years or even decades after symptoms first appear. The lack of a single definitive test, combined with inconsistent use of diagnostic criteria across healthcare systems, compounds the problem.
Long-Term Health Risks
PCOS is not just a reproductive condition. It carries significant metabolic consequences that accumulate over time. More than half of women with PCOS develop type 2 diabetes by age 40, according to the CDC. The connection runs through insulin resistance: the same hormonal imbalance that disrupts ovulation also impairs how the body processes blood sugar.
PCOS is also the leading cause of ovulatory infertility. Among women who have trouble conceiving because they aren’t ovulating regularly, 70% to 80% have PCOS. That doesn’t mean most women with PCOS can’t have children. Many conceive with lifestyle changes or fertility treatments. But it does mean that PCOS dominates this particular category of infertility.
The Economic Scale
The sheer number of women affected translates into substantial healthcare costs. In the United States alone, the total economic burden of PCOS is estimated at $8 billion per year. About $3.7 billion of that goes toward initial diagnosis and managing hormonal symptoms. The remaining $4.3 billion covers pregnancy complications and long-term conditions like diabetes, cardiovascular disease, and mental health care that women with PCOS need at higher rates than the general population.